ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
-1.03%
Bitcoin
62,625.48
5.93%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Sorrento Therapeutics Inc (SRNE)

  7. Sorrento Therapeutics Inc (SRNE) Noticias

SRNE

Sorrento Therapeutics (SRNE)

Sorrento Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SRNE
FechaHoraFuenteTítuloSímboloCompañía
03/11/202316:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SRNESorrento Therapeutics Inc
07/08/202315:15Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:SRNESorrento Therapeutics Inc
21/06/202316:25Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:SRNESorrento Therapeutics Inc
20/06/202316:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SRNESorrento Therapeutics Inc
05/06/202308:00GlobeNewswire Inc.Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the ANASDAQ:SRNESorrento Therapeutics Inc
15/05/202314:18Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SRNESorrento Therapeutics Inc
09/05/202305:03Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:SRNESorrento Therapeutics Inc
12/04/202307:51Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:SRNESorrento Therapeutics Inc
10/04/202316:23Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:SRNESorrento Therapeutics Inc
20/03/202318:54Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SRNESorrento Therapeutics Inc
10/03/202310:22Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SRNESorrento Therapeutics Inc
22/02/202308:25AllPennyStocks.comBankruptcy Court Approval Causes Premarket Buying PressureNASDAQ:SRNESorrento Therapeutics Inc
21/02/202316:57PR Newswire (US)Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 CaseNASDAQ:SRNESorrento Therapeutics Inc
20/02/202310:00GlobeNewswire Inc.Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)NASDAQ:SRNESorrento Therapeutics Inc
20/02/202310:00GlobeNewswire Inc.Sorrento Issues Update to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)NASDAQ:SRNESorrento Therapeutics Inc
16/02/202313:41PR Newswire (US)Sorrento Therapeutics, Inc. Receives Court Approval for "First Day" Employee Wages and Cash Management MotionsNASDAQ:SRNESorrento Therapeutics Inc
13/02/202314:46GlobeNewswire Inc.Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.NASDAQ:SRNESorrento Therapeutics Inc
12/02/202317:48GlobeNewswire Inc.Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraineNASDAQ:SRNESorrento Therapeutics Inc
04/02/202321:48GlobeNewswire Inc.Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of StockholdersNASDAQ:SRNESorrento Therapeutics Inc
03/02/202319:59GlobeNewswire Inc.Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common StockNASDAQ:SRNESorrento Therapeutics Inc
02/02/202312:15GlobeNewswire Inc.Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common StockNASDAQ:SRNESorrento Therapeutics Inc
29/01/202321:26GlobeNewswire Inc.Sorrento Issues “FAQ” Regarding the Dividend of Scilex Holding Company Common StockNASDAQ:SRNESorrento Therapeutics Inc
29/01/202320:55GlobeNewswire Inc.Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common StockNASDAQ:SRNESorrento Therapeutics Inc
09/01/202308:00GlobeNewswire Inc.Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir BoostingNASDAQ:SRNESorrento Therapeutics Inc
19/12/202205:03Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:SRNESorrento Therapeutics Inc
06/12/202208:00GlobeNewswire Inc.Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 VirusNASDAQ:SRNESorrento Therapeutics Inc
05/12/202214:01GlobeNewswire Inc.Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)NASDAQ:SRNESorrento Therapeutics Inc
29/11/202213:06GlobeNewswire Inc.Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir BoNASDAQ:SRNESorrento Therapeutics Inc
13/11/202214:02GlobeNewswire Inc.Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid ArthritisNASDAQ:SRNESorrento Therapeutics Inc
10/11/202213:45GlobeNewswire Inc.Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), Debuts on Nasdaq Under Ticker “SCLX”NASDAQ:SRNESorrento Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SRNE

Su Consulta Reciente

NASDAQ
NVDA
NVIDIA
NYSE
XOM
Exxon Mobil
USOTC
BASFY
BASF (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
CCOM
US30
US 30
AMEX
XLF
Financial Select Sector
NYSE
AXP
American Express
AMEX
XLV
Health Care Select Sector
NYSE
CVX
Chevron
NYSE
NKE
Nike
NYSE
KO
Coca Cola
USOTC
RHHBY
Roche (QX)
NASDAQ
AMZN
Amazon.com
USOTC
ADDYY
Adidas (QX)
NYSE
MCD
McDonalds
USOTC
BNPQY
BNP Paribas (QX)
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados